Company news

Alvotech news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)

March 25, 2025

UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)

March 25, 2025

Alvotech Reports Record Results for 2024 and Provides Business Update

March 25, 2025

Alvotech Reports Record Results for 2024 and Provides Business Update

March 25, 2025

Alvotech Acquires Xbrane’s R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production

March 19, 2025

Alvotech and Dr. Reddy’s Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

March 17, 2025

Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

March 17, 2025

Alvotech Meeting Investors and Participates in Fireside Chat At Barclays 27th Global Healthcare Conference in Miami, Florida

March 6, 2025

Alvotech to Report Full Year Financial Results for 2024 on March 26, 2025, and Hosts Conference Call on March 27, 2025, at 8: 00 am ET

February 23, 2025

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

February 20, 2025

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

February 17, 2025

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)

January 26, 2025

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)

January 26, 2025

Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024

December 22, 2024

Alvotech Reports Financial Results for the First Nine Months of 2024

November 12, 2024

Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024

November 6, 2024

European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)

November 3, 2024

Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8: 00 am ET

October 29, 2024

Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024

October 24, 2024

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)

October 21, 2024

European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

October 9, 2024

Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio®

September 24, 2024

Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

August 25, 2024

European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

August 14, 2024

Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024

August 14, 2024

Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8: 00 am ET

July 31, 2024

STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe

July 21, 2024

Alvotech Announces Closing of Private Debt Financing

July 10, 2024

Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®

July 1, 2024

Alvotech Issues New Shares to Holders of Convertible Bonds

June 30, 2024

Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024

June 30, 2024

Alvotech Receives Conversion Notices for Majority of Convertible Bonds

June 25, 2024

Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe

June 17, 2024

Alvotech and STADA add to Strategic Alliance through Denosumab Partnership

June 10, 2024

Alvotech and STADA add to strategic alliance through denosumab partnership

June 10, 2024

Alvotech Announces Strategic Refinancing Agreement

June 6, 2024

Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024

May 28, 2024

Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update

May 20, 2024

Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK

May 20, 2024

Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK

May 20, 2024

Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.

May 19, 2024

Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.

May 19, 2024

Alvotech S.A. Annual General Meeting to be held June 7, 2024

May 14, 2024

Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8: 00 am EDT (12 noon GMT)

May 12, 2024

Alvotech Announces Participation at BofA Securities Healthcare Conference 2024

May 1, 2024

U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)

April 29, 2024

Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)

April 23, 2024

Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)

April 18, 2024

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)

April 15, 2024

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)

April 15, 2024

← Newer news releases · Older news releases →

Calls

The 5 newest of 17 calls. Every call is listed under its year.

Decks

The 5 newest of 11 decks. Every deck is listed under its year.